1. Scrip
  2. >>Business
  3. >>Stock Watch

Stock Watch: Pharma Businesses That Leave Consumer Behind

Corporate Simplification Risks Discarding Some Valuable And Defensive Attributes

 
• By Andy Smith

Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.    

Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

Masimo Corp.’s recent announcement of the separation of its consumer business marked the latest in a long line of corporate simplifications by former healthcare conglomerates that look likely to be extended by Sanofi’s spin-off of its consumer healthcare business. (Also see "Sanofi Awaiting Key Meeting With FDA To Recommence Cialis Switch" - HBW Insight, 5 February, 2024.) The higher profitability of a pure-play pharmaceutical group after the departure of lower-margin consumer product franchises is often-cited as the transaction’s main advantage. For example, in the four quarters after GSK plc’s* Haleon plc Consumer Healthcare spin-off in July 2022, its continuing earnings per share grew by 55% on the previous period, although its turnover fell by 17%. But there are disadvantages too.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Stock Watch

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly

 
• By Andy Smith

The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.

Stock Watch: How Tariff Threat Might Boost Pharma Q1

 
• By Andy Smith

Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.

Stock Watch: Are Gene Therapy Prices Too High For Success?

 
• By Andy Smith

The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.

Stock Watch: Bayer’s Movable Goalposts

 
• By Andy Smith

After lowering its full-year earnings guidance just six weeks before the end of 2024, Bayer, by talking up of the prospects for its new drug launches and a major clinical trial result in 2025, might risk damaging its integrity further.

More from Business

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

Sanofi Licenses Bispecific Candidates From AI-Driven Earendil

 
• By Joseph Haas

Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.